Allcyte GmbH operates in the biotechnology sector, specializing in functional drug testing for cancer treatment. The company serves two primary client groups: physicians treating cancer patients and pharmaceutical companies developing new drugs. Allcyte's core technology, called pharmacoscopy, measures the action of drugs in viable primary human tissue samples at the single-cell level. This approach aims to predict clinical drug activity before human trials, offering a significant advantage over traditional genetic-driven precision medicine, which often lacks precise answers. The business model revolves around providing actionable insights that help physicians select the most effective drugs for their patients and assist pharmaceutical companies in identifying the most promising drug candidates for clinical development. Allcyte generates revenue through service fees charged to both healthcare providers and pharmaceutical firms for utilizing its platform. The company operates primarily in the oncology market, focusing on improving patient outcomes and increasing the success rates of clinical studies.

Keywords: functional drug testing, cancer treatment, pharmacoscopy, single-cell analysis, clinical translatability, oncology, precision medicine, drug development, patient outcomes, biotechnology.